Victor Vaughn Sells 5,750 Shares of Supernus Pharmaceuticals Inc (SUPN) Stock

Supernus Pharmaceuticals Inc (NASDAQ:SUPN) VP Victor Vaughn sold 5,750 shares of the business’s stock in a transaction that occurred on Friday, January 12th. The shares were sold at an average price of $45.03, for a total value of $258,922.50. Following the completion of the transaction, the vice president now owns 15,094 shares of the company’s stock, valued at $679,682.82. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Victor Vaughn also recently made the following trade(s):

  • On Tuesday, January 9th, Victor Vaughn sold 15,000 shares of Supernus Pharmaceuticals stock. The shares were sold at an average price of $42.04, for a total value of $630,600.00.
  • On Tuesday, January 2nd, Victor Vaughn sold 55,000 shares of Supernus Pharmaceuticals stock. The shares were sold at an average price of $40.11, for a total value of $2,206,050.00.

Shares of Supernus Pharmaceuticals Inc (SUPN) opened at $46.50 on Thursday. Supernus Pharmaceuticals Inc has a 12 month low of $23.10 and a 12 month high of $50.04. The stock has a market capitalization of $2,380.00, a P/E ratio of 42.27 and a beta of 1.17.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings data on Monday, November 6th. The specialty pharmaceutical company reported $0.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.27 by $0.02. Supernus Pharmaceuticals had a return on equity of 26.37% and a net margin of 20.98%. The company had revenue of $80.40 million for the quarter, compared to analysts’ expectations of $78.74 million. The business’s quarterly revenue was up 41.5% on a year-over-year basis. equities analysts expect that Supernus Pharmaceuticals Inc will post 1.07 earnings per share for the current year.

Institutional investors have recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Supernus Pharmaceuticals by 278.2% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,018 shares of the specialty pharmaceutical company’s stock worth $130,000 after purchasing an additional 2,220 shares in the last quarter. Riverhead Capital Management LLC raised its stake in shares of Supernus Pharmaceuticals by 91.4% during the 2nd quarter. Riverhead Capital Management LLC now owns 3,062 shares of the specialty pharmaceutical company’s stock worth $132,000 after purchasing an additional 1,462 shares in the last quarter. Advisor Group Inc. raised its stake in shares of Supernus Pharmaceuticals by 13.7% during the 2nd quarter. Advisor Group Inc. now owns 3,395 shares of the specialty pharmaceutical company’s stock worth $145,000 after purchasing an additional 410 shares in the last quarter. Victory Capital Management Inc. raised its stake in shares of Supernus Pharmaceuticals by 17.7% during the 2nd quarter. Victory Capital Management Inc. now owns 3,441 shares of the specialty pharmaceutical company’s stock worth $148,000 after purchasing an additional 517 shares in the last quarter. Finally, Flinton Capital Management LLC raised its stake in shares of Supernus Pharmaceuticals by 88.9% during the 2nd quarter. Flinton Capital Management LLC now owns 4,760 shares of the specialty pharmaceutical company’s stock worth $205,000 after purchasing an additional 2,240 shares in the last quarter. Institutional investors own 98.22% of the company’s stock.

A number of equities analysts have weighed in on the company. Cowen reaffirmed a “buy” rating and set a $50.00 price target on shares of Supernus Pharmaceuticals in a research report on Thursday, September 21st. Jefferies Group reaffirmed a “buy” rating and set a $51.00 price target on shares of Supernus Pharmaceuticals in a research report on Wednesday, September 20th. FBR & Co assumed coverage on Supernus Pharmaceuticals in a research report on Thursday, October 19th. They set a “buy” rating and a $53.00 price target for the company. Cantor Fitzgerald reaffirmed a “buy” rating and set a $49.00 price target on shares of Supernus Pharmaceuticals in a research report on Wednesday, September 27th. Finally, Stifel Nicolaus raised Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $47.00 price target for the company in a research report on Tuesday, November 7th. Three analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Supernus Pharmaceuticals currently has an average rating of “Buy” and an average price target of $49.90.

ILLEGAL ACTIVITY WARNING: This piece of content was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another website, it was stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/01/18/victor-vaughn-sells-5750-shares-of-supernus-pharmaceuticals-inc-supn-stock.html.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Insider Buying and Selling by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply